Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 84 Florida 69 Colorado 41 Texas 40 Massachusetts 38
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca5 Pfizer3 Eli Lilly and Company2 Genentech, Inc.2 Hoffmann-La Roche2
State
California84 Florida69 Colorado41 Texas40 Massachusetts38
All 47 states
Target enrolment
to

Trials with a site in New York

34 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
NCT07781852Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
Lumina Pharmaceuticals Inc
Early Phase 1
40
Massachusetts, Michigan, New York
2026-09-01
Not yet open
AURA Health Technologies
Observational
100
New York
2026-05
Recruiting
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Recruiting
EXoPERT EMERALD Clinical Study
NCT07186296Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
EXoPERT
Observational
1,400
California, Hawaii, Kentucky, Maryland, New York
2025-05-09
Active, closed
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Michigan, New York, Pennsylvania, Tennessee
2025-01-14
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer
NextCure, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Active, closed
Pfizer
Observational
1
New York
2024-06-24
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
858 Therapeutics, Inc.
Phase 1/2
120
Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio
2024-05-13
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington
2024-02-26
Active, closed
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
Hoffmann-La Roche
Phase 2
83
California, New York, North Carolina, South Dakota
2023-07-18
Active, closed
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT05720039Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease
Intuitive Surgical
Not applicable
204
California, Florida, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2023-05-08
Recruiting
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
DrugsAbemaciclib·Fulvestrant
Incyclix Bio
Phase 1/2
150
Florida, Georgia, Indiana, Massachusetts, Michigan, New York, North Carolina, Ohio
2023-03-28
By invitation
Tolmar Inc.
Phase 3
250
California, Florida, Kentucky, Maryland, New York, North Carolina, Pennsylvania, Tennessee
2022-12-28
Recruiting
Comprehensive Outcomes for After Cancer Health
NCT05349227Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
Pack Health
Not applicable
625
Florida, Massachusetts, Nebraska, New York, Ohio, Texas
2022-06-23
Recruiting
Eli Lilly and Company
Phase 1
260
Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Missouri, New York
2022-05-11
Active, closed
NGM Biopharmaceuticals, Inc
Phase 1
130
Arizona, California, Florida, Michigan, New York, Oklahoma, Texas
2022-03-31
Recruiting
Regor Pharmaceuticals Inc.
Phase 1
64
California, Florida, Georgia, Massachusetts, Missouri, New York
2022-03-04
Active, closed
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT05239143Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
DrugRimiducid
Poseida Therapeutics, Inc.
Phase 1
180
California, Colorado, Iowa, Kansas, Maryland, Massachusetts, Nebraska, New York
2022-02-15
Recruiting
AstraZeneca
Phase 1/2
460
California, Louisiana, Maryland, Massachusetts, Missouri, New Mexico, New York, North Carolina
2021-10-18
Active, closed
AstraZeneca
Phase 3
732
California, Florida, Georgia, Massachusetts, Michigan, New York, Ohio, Oregon
2021-10-18
Active, closed
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
New York, Texas, Washington
2021-07-16
Active, closed
Tolmar Inc.
Phase 3
250
California, Colorado, Illinois, Kentucky, Maryland, Nebraska, New York, Ohio
2021-07-01
Active, closed
Breast Cancer Index (BCI) Registry
NCT04875351Breast Cancer
Biotheranostics, Inc.
Observational
3,465
Alabama, Arizona, California, Colorado, Florida, Illinois, Maryland, New York
2021-04-14
Active, closed
AstraZeneca
Phase 1/2
702
Massachusetts, New York, Oklahoma, Texas
2020-11-12
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
DrugsPF-07104091·Palbociclib·Letrozole·Fulvestrant
Pfizer
Phase 2
157
Iowa, Kentucky, Massachusetts, New Jersey, New York, Virginia
2020-09-16
Active, closed
AstraZeneca
Phase 3
185
Florida, Maryland, Michigan, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island
2020-08-04
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
DrugTemozolomide
Sapience Therapeutics
Phase 1/2
125
California, Colorado, Illinois, Michigan, New York, North Carolina, Tennessee
2020-07-01
Active, closed
Hoffmann-La Roche
Phase 2/3
325
California, Massachusetts, New York, North Carolina, Tennessee, Texas, Washington
2020-01-29
Active, closed
Genentech, Inc.
Phase 1
181
Colorado, Massachusetts, New York, Tennessee
2017-11-24
Active, closed
Genentech, Inc.
Phase 1
200
Massachusetts, New York, Tennessee
2016-12-13
Active, closed
Incyte Corporation
Phase 2
10
California, Kentucky, New York, Tennessee, Texas
2016-11-30
Active, closed
Eli Lilly and Company
Phase 1
100
Arkansas, California, Colorado, Massachusetts, Michigan, New York
2016-11-14
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in New York that also match the filters currently applied.

How many clinical trials are recruiting in New York?

10 of the 34 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 21 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New York), 34 studies
PhaseStudiesRecruitingShare
Phase 110329.4%
Phase 1/26317.6%
Phase 25114.7%
Phase 35114.7%
Observational4111.8%
Not applicable215.9%
Early Phase 1102.9%
Phase 2/3102.9%

Most active sponsors

Lead sponsors with the most studies (New York)
Lead sponsorStudiesRecruiting
AstraZeneca52
Pfizer30
Eli Lilly and Company21
Genentech, Inc.20
Hoffmann-La Roche20
Tolmar Inc.20
858 Therapeutics, Inc.11
AURA Health Technologies10
Avacta Life Sciences Ltd10
BicycleTx Limited10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.